The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - RAPT Therapeutics
Stock and Other Ownership Interests - RAPT Therapeutics
Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Bluebird Bio; Carolina BioOncology Institute; Juno Therapeutics; Kite, a Gilead company; Lion Biotechnologies; ZIOPHARM Oncology
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Curis; Genentech/Roche; TopAlliance BioSciences Inc
Speakers' Bureau - Bristol-Myers Squibb; Dendreon; Genentech/Roche; Merck
Research Funding - Abbvie; Alkermes; Arcus Biosciences; AstraZeneca/MedImmune; Atreca (Inst); Bristol-Myers Squibb; Corvus Pharmaceuticals; Curis; EMD Serono; FLX Bio; Genentech/Roche; Incyte; Lilly/ImClone; Macrogenics; Seagen; Tempest Therapeutics; Top Alliance BioScience
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
Other Relationship - Ongoing discussions with potential future biopharma and biotech for Human Applications Lab sponsored projects
 
Bartosz Chmielowski
Consulting or Advisory Role - Array BioPharma; Biothera; Compugen; Deciphera; Epizyme; HUYA Bioscience International; IDEAYA Biosciences; Iovance Biotherapeutics; Janssen; Regeneron
Speakers' Bureau - Janssen Oncology; Sanofi/Regeneron
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly/ImClone (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Rgenix (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Compugen; Deciphera; Epizyme; HUYA Bioscience International; IDEAYA Biosciences; Iovance Biotherapeutics; Regeneron
 
Julie R. Brahmer
Honoraria - Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech; Janssen Oncology; Lilly; Merck; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Revolution; Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Janssen Oncology; merck
 
Sarina Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Samantha Elizabeth Bowyer
No Relationships to Disclose
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; Immunome; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Daniel V.T. Catenacci
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Tempus
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Genentech; Guardant Health; Lilly; Merck; Tempus
 
Christina Wu
Consulting or Advisory Role - Array BioPHarma
Research Funding - Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Lycera (Inst); RAPT Therapeutics (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Symphogen (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - Array BioPharma
 
Minal A. Barve
No Relationships to Disclose
 
Michael Jon Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Nicole Nasrah
No Relationships to Disclose
 
Dan Johnson
Employment - RAPT Therapeutics
Stock and Other Ownership Interests - RAPT Therapeutics
 
William Ho
Employment - RAPT Therapeutics
Leadership - RAPT Therapeutics
Stock and Other Ownership Interests - RAPT Therapeutics